About the Study: Among adults with HIV at risk of treatment-associated weight gain, does an alternative first-line regimen produce less weight gain than treatment combinations containing an integrase strand transfer inhibitor (eg, dolutegravir or bictegravir) along with tenofovir alafenamide? In this noninferiority randomized clinical trial including 600 adults with HIV, initiating a regimen with doravirine, lamivudine, and tenofovir disoproxil fumarate was noninferior to a regimen with dolutegravir, emtricitabine, and tenofovir alafenamide for viral suppression (HIV RNA level <50 copies/mL) at 48 weeks (89.0% vs 90.7%, respectively, meeting the prespecified noninferiority margin of −10 percentage points), and was associated with less weight gain. Among adults initiating antiretroviral therapy, a regimen with doravirine, lamivudine, and tenofovir disoproxil fumarate was noninferior to a regimen with dolutegravir, emtricitabine, and tenofovir alafenamide for viral suppression at 48 weeks and was associated with less weight gain.
Meeting Information:
This paper will be presented at International Aids Society (IAS).
